Skip to main content
. 2015 Feb 17;33(10):1112–1118. doi: 10.1200/JCO.2014.58.4904

Fig A1.

Fig A1.

(A) Progression-free survival (PFS) inference and external validation for arm treated with fluorouracil plus oxaliplatin (FOLFOX) or capecitabine plus oxaliplatin (XELOX), with addition of bevacizumab (data adapted6,23), and (B) internal validation with simulation results for arm treated with FOLFOX or XELOX in first-line model (data adapted6,8). (C) Internal validation of overall survival (OS) in second-line model (data adapted9).